20837944

Source:http://linkedlifedata.com/resource/pubmed/id/20837944

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0205179, umls-concept:C0280100, umls-concept:C0671970, umls-concept:C0920321, umls-concept:C1176020
pubmed:issue	29
pubmed:dateCreated	2010-10-8
pubmed:abstractText	This open-label, phase I, dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of sunitinib in combination with capecitabine in patients with advanced solid tumors.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine, http://linkedlifedata.com/resource/pubmed/chemical/sunitinib
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1527-7755
pubmed:author	pubmed-author:BelloAkintundeA, pubmed-author:BurrisHoward AHA, pubmed-author:ChaoRichardR, pubmed-author:ChioreanE GabrielaEG, pubmed-author:JonesSuzanneS, pubmed-author:LeeFa ChyiFC, pubmed-author:LiauKatherine FKF, pubmed-author:RoyceMelanieM, pubmed-author:SweeneyChristopher JCJ, pubmed-author:TyeLesleyL, pubmed-author:VerschraegenClaire FCF
pubmed:issnType	Electronic
pubmed:day	10
pubmed:volume	28
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4513-20
pubmed:dateRevised	2011-10-10
pubmed:meshHeading	pubmed-meshheading:20837944-Administration, Oral, pubmed-meshheading:20837944-Adult, pubmed-meshheading:20837944-Aged, pubmed-meshheading:20837944-Aged, 80 and over, pubmed-meshheading:20837944-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20837944-Area Under Curve, pubmed-meshheading:20837944-Deoxycytidine, pubmed-meshheading:20837944-Diarrhea, pubmed-meshheading:20837944-Dose-Response Relationship, Drug, pubmed-meshheading:20837944-Drug Administration Schedule, pubmed-meshheading:20837944-Fatigue, pubmed-meshheading:20837944-Female, pubmed-meshheading:20837944-Fluorouracil, pubmed-meshheading:20837944-Humans, pubmed-meshheading:20837944-Indoles, pubmed-meshheading:20837944-Male, pubmed-meshheading:20837944-Metabolic Clearance Rate, pubmed-meshheading:20837944-Middle Aged, pubmed-meshheading:20837944-Nausea, pubmed-meshheading:20837944-Neoplasms, pubmed-meshheading:20837944-Pyrroles, pubmed-meshheading:20837944-Treatment Outcome, pubmed-meshheading:20837944-Vomiting, pubmed-meshheading:20837944-Young Adult
pubmed:year	2010
pubmed:articleTitle	A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
pubmed:affiliation	Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA. Christopher_Sweeney@dfci.harvard.edu
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I